Osteoporosis Drug Unexpectedly Drives Arthritis (2 of 2) (IMAGE)
Caption
Blocking bone breakdown. (A) Inflamed synovial tissue stimulates local bone resorption and suppresses bone formation at sites where it touches the bone surface. This leads to erosions in the bone tissue below the articular cartilage. (B) TNFα directly stimulates bone resorption by osteoclasts and increases RANKL secretion by fibroblast-like synoviocytes, both of which further increase bone resorption. However, TNFα also induces these synoviocytes to express sclerostin, which is not only an inhibitor of osteoblastic bone formation but also diminishes TNFα signaling in synoviocytes. Thus, sclerostin indirectly helps to limit bone resorption activity by osteoclasts. This material relates to a paper that appeared in the March 16, 2016, issue of Science Translational Medicine, published by AAAS. The paper, by C. Wehmeyer at University Hospital Muenster in Muenster, Germany, and colleagues was titled, "Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction."
Credit
F. Rauch <i>et al., Science Translational Medicine</i> (2016)
Usage Restrictions
Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.
License
Licensed content